Recent Updates — IVA
Inventiva S.A. reported unaudited first-half 2026 financial results on September 28, 2026, recording a net loss of €69.5 million compared to €175.9 million in the prior year period. The company generated €20,000 in revenues and incurred €46.2 million in research and development expenses. Inventiva completed a comprehensive refinancing transaction on June 2, 2026, which included an equity offering of 27,272,727 ADSs at $4.40 per share for net proceeds of $110.9 million (€95.3 million), and the issuance of Tranches A and B of senior secured convertible bonds totaling €75.0 million in gross proceeds. The company also repaid its existing European Investment Bank loan of €62.2 million and repurchased warrants for €50.0 million. As of June 30, 2026, cash and cash equivalents stood at €166.1 million with €67.8 million in short-term deposits, providing a cash runway through the second quarter of 2027. The company expects topline results from its pivotal Phase III NATiV3 clinical trial for lanifibranor in MASH in the fourth quarter of 2026. Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis.
Inventiva announced the completion of the last patient's final 72-week visit in its NATiV3 Phase 3 clinical trial for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The trial enrolled 1,009 patients in the main cohort and 410 in an exploratory cohort. Topline results are expected in Q4 2026, with potential regulatory submission in H1 2027 and a U.S. launch in 2028 if approved. The company also updated its H1 2026 financial results date to September 28, 2026. Inventiva is a clinical-stage biopharmaceutical company focused on developing therapies for MASH.
Inventiva S.A. appointed Chris Benecchi as Chief Operating Officer on August 31, 2026. Mr. Benecchi will lead operational readiness ahead of the expected Q4 2026 topline results from the pivotal NATiV3 Phase 3 trial for lanifibranor and prepare for a potential U.S. launch in 2028, subject to regulatory approval. He brings 30 years of biopharmaceutical leadership experience, previously serving as CEO of Motric Bio and holding senior roles at Sage Therapeutics, UCB, Alexion, Acorda Therapeutics, Takeda Pharmaceuticals, and Johnson & Johnson. Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Inventiva S.A. reported preliminary financial results for the first half of 2026, recording zero revenues compared to €4.5 million in the prior year period. The company held €166.1 million in cash and cash equivalents plus €67.8 million in short-term deposits as of June 30, 2026. Net cash used in operating activities was (€48.7) million, a decrease from (€53.7) million in the same period last year, driven by an €8.8 million working capital change that partially offset increased R&D expenses of €50.1 million related to the NATiV3 Phase 3 clinical trial for MASH. Financing activities generated €50.9 million, reflecting proceeds from a June 2026 equity offering and debt financing, which were used to repay a €62 million EIB loan and repurchase warrants. The company expects its current resources to fund operations through the end of Q2 2027, or until early Q1 2028 if additional potential proceeds from Tranche C debt and warrant exercises are realized. Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis.